What is Alebund Pharmaceuticals?
Alebund Pharmaceuticals operates as a clinical-stage biopharmaceutical organization dedicated to the discovery and development of novel therapeutic interventions. The company maintains a primary focus on nephrology, specifically targeting kidney diseases and their systemic complications, while also exploring broader applications for other chronic conditions. By leveraging a science-driven approach, Alebund aims to address significant unmet medical needs, positioning itself as a key player in the specialized healthcare sector. Its market position is bolstered by a robust portfolio of research-oriented partnerships and a strategic focus on high-impact therapeutic areas.
How much funding has Alebund Pharmaceuticals raised?
Alebund Pharmaceuticals has raised a total of $184.6M across 3 funding rounds:
Series B
$60M
Other Financing Round
$54.5M
Series C
$70.1M
Series B (2021): $60M with participation from Lilly Asia Ventures, 3E Bioventures Capital, Quan Capital, Sherpa Healthcare Partners, and Med-Fine Capital
Other Financing Round (2021): $54.5M led by YuanBio Venture Capital, Loyal Valley Capital, Morningside Ventures, and 3H Health Investment
Series C (2025): $70.1M, investors not publicly disclosed
Key Investors in Alebund Pharmaceuticals
Lilly Asia Ventures
Lilly Asia Ventures is a prominent biomedical venture capital firm with a global footprint, focused on partnering with entrepreneurs to develop breakthrough products that improve human health.
3E Bioventures Capital
3E Bioventures Capital employs a science-driven investment philosophy, providing expertise and capital efficiency to companies addressing significant unmet medical needs across the Pacific.
Loyal Valley Capital
Loyal Valley Capital is a research-oriented private equity firm that serves as a strategic partner for high-growth companies, with a strong track record in the life sciences and technology sectors.
What's next for Alebund Pharmaceuticals?
With the successful closure of this major enterprise-level funding, Alebund Pharmaceuticals is expected to prioritize the advancement of its clinical trial pipeline. The strategic deployment of these funds will likely focus on accelerating phase-specific development milestones, enhancing regulatory engagement, and potentially expanding its internal R&D infrastructure. As the company transitions into more advanced clinical stages, the focus will shift toward demonstrating efficacy and safety profiles that can support future commercialization efforts. Investors will be closely monitoring the firm's ability to maintain its research momentum while navigating the complex regulatory environments inherent in global drug development.
See full Alebund Pharmaceuticals company page
